The Ovary Is Surprisingly Active After Menopause. Scientists Are Trying to Figure Out Why

This guide maps the WIRED report on postmenopausal ovary activity and separates known effects from open questions. It applies the verify-before-you-commit rule: confirm the live, complete option and compare like-for-like totals and terms.

How It Works

The mechanism comes down to what the ovary is made of. Before menopause, most of its hormone output comes from developing follicles, the structures that mature and release eggs. Once the follicle supply is exhausted, cyclic estrogen production ends. What remains is the stroma — the ovary's connective-tissue core — along with interstitial and theca-type cells, which do not need follicles to function. Those cells can secrete androgens such as testosterone and androstenedione, and they retain the capacity to convert androgens into estrogens. The output is far smaller than a cycling ovary's, but it is not zero, which is part of why menopause remains an evolutionary puzzle, as National Geographic has noted.

That residual output is why the finding matters. WIRED reports that the hormones the ovary produces after menopause are generally known to help maintain libido, bone, and muscle, among other things — while noting it is not clear how much the relatively small amount of postmenopausal ovarian hormone contributes to those effects. That gap is the mechanism's central open question: a signal can be genuine and still be too small, or too locally acting, to move a whole-body outcome on its own.

Because the debate turns on measurement, the terms matter as much as the biology.

When you read a claim that the postmenopausal ovary is "active," check what was measured and in whom. A blood level of a hormone is not the same as the rate at which a tissue makes it, and circulating estrogen arrives from several sources — the ovary, the adrenal glands, and conversion in fat. Research that includes women whose ovaries were surgically removed gives a cleaner read on what the ovary itself contributes; studies without that group cannot separate the sources. Compare like with like: a total measured one way against a total measured the same way, in comparable groups, rather than a tissue finding against a blood finding.

The practical rule follows from the mechanism itself. Establish which tissue produces which hormone, confirm the measurement actually matches the claim, and only then decide what the headline means for you. The biology is verifiable; the size of the effect is still being worked out.

Key Factors to Consider

Before you commit — to a supplement, a monitoring plan, a clinician's recommendation, or a research-backed routine — score the claim against three criteria. This section lists only the criteria and the numbers behind them; applying them to a specific product or program belongs elsewhere.

Criterion 1: a measured quantity, not a description. WIRED's reporting on postmenopausal ovarian activity notes that it is "not clear how much" the relatively small hormone output contributes. A claim you cannot put a unit on is a claim you cannot verify. Ask for the value, the unit, the reference range it is being compared against, and the baseline it improved on. If any of those four is missing, treat the claim as unverified and hold your commitment.

Criterion 2: attribution. Ask whether the number describes the ovary's own output or the body as a whole. If the source does not separate the two, the figure cannot support a decision about the ovary specifically. A total-body measurement is still useful, but it answers a different question than the one in front of you.

Criterion 3: an endpoint you would act on. WIRED notes that postmenopausal ovarian hormones are known to help maintain libido, bone, and muscle. Require the claim to name which of those it addresses and to show a change from baseline to follow-up — not a single snapshot, and not a general statement that hormones "support" something.

The numbers that matter. Ask for sample size, study duration, and whether participants were postmenopausal at entry rather than perimenopausal; a mixed group muddies the result. Ask for the size of the change, not just its direction. And keep one population-level figure in view: Prevention, in coverage syndicated on Yahoo Health, cited data suggesting women gain an average of about a pound a year across this life stage — useful context for judging whether a claimed benefit is meaningful against that backdrop. When a source supplies none of these numbers, say so plainly and decide on the method alone.

Common Mistakes

The most expensive mistake in this area is committing to a product or a routine because a headline called the ovary "active" after menopause, without checking what the underlying source actually measured. A concrete example: a supplement page that leans on the WIRED report and claims it can "support postmenopausal ovarian activity." WIRED's story describes what researchers observe the ovary doing on its own; it does not describe a lever a pill can pull. The check is one question — did the study measure hormone output coming from the ovary itself, or did it measure a change after an intervention? If it is the former, you have learned that the ovary is doing something, not that any product changes it.

The second half of that same mistake is assuming a real but small output does the work a full supply once did. WIRED notes that the hormones the postmenopausal ovary produces are known to help maintain libido, bone, and muscle, but that it is not clear how much the relatively small amounts contribute. Concrete example: someone reads that and drops a resistance-training habit or puts off a bone density scan, reasoning that the ovary has the bone and muscle category covered. The check: get your own baseline first — bone density, a strength or function measure, symptom notes — then ask whether the observed contribution is large enough to move your numbers. Without a baseline, you cannot tell whether the ovary is carrying the load or whether something else needs to.

The second pitfall is averaging figures that come from different populations and calling it a comparison. A Prevention report on Yahoo Health cites data suggesting women gain an average of a pound a year during the menopausal transition, and separately covers research on tirzepatide in postmenopausal women. Those are not the same measurement, and lining them up side by side tells you nothing about your own case. Before you commit to either, match the time window, the population, and the outcome being measured — scale weight is not the same as body composition, and a transition average is not the same as a trial result.

Run one habit before you spend money or change a routine: write down the exact claim you are acting on, the source, and what that source measured. If the source observed the ovary and you are buying an intervention, the totals do not match — and that mismatch, not the headline, is what you would be paying for.

Insider Tactics

The non-obvious strategy here is to audit the measurement instead of the marketing. Before you commit to a supplement, a monitoring plan, or a new routine, ask — in writing — which hormone was measured, which assay measured it, and in which population. WIRED's reporting notes that the hormones the ovary produces after menopause are understood to help maintain libido, bone, and muscle, but adds that it is not clear how much the relatively small output contributes. A pitch that converts that open question into a promise is running ahead of the evidence. Make the seller, or the study, close the gap first.

The second tactic is to request the postmenopausal-only subgroup. Published summaries often pool participants across life stages, and a result that holds for the whole group can shrink or disappear when the analysis is restricted to postmenopausal women. Ask for the postmenopausal participant count behind the figure, and ask whether every sample ran through the same laboratory and the same batch. Batch-to-batch drift can look like a biological change, so a finding that survives only across mixed batches is not one to act on. No subgroup data means no verification.

On timing: establish your baseline before you start anything, and timestamp it. Write down the date, the time of day, the lab name, the assay name, and whether you were fasting. Those five fields are what make a later result a like-for-like comparison. Without them, you are comparing a fresh number to a memory.

A second timing tip concerns the study's clock rather than yours. Check the interval between measurements in the paper you are relying on. A change captured at a single time point can be noise; one that reproduces across multiple intervals and separate samples is harder to dismiss. Set your own re-check to the shortest interval the study actually supports, not to a marketer's calendar.

Finally, write an exit condition and a re-check date into the plan before you commit: state what result would make you stop, and when you will measure again. Then hold to it. A commitment with a defined exit is easy to reverse; one without it is not.

Comparison

Line up the three realistic options on a 12-month clock and the comparison does most of the work: an ovarian-support supplement bought on the strength of the headline, a monitored clinical plan with a baseline and repeat measures, or deliberate waiting with a written revisit date. The point of the table is not to rank claims — it is to make the totals and terms visible before money moves.

The supplement wins in exactly one configuration: the full annual total is published, the renewal and cancellation terms are in writing, and you are using it alongside a plan that already measures your endpoint. Absent all three, you are comparing an unverified total against a verified one, which is not a comparison.

The monitored plan wins on like-for-like terms because it produces data from your body. That matters against the background rate: one pound a year is roughly what midlife drift supplies on its own, so a single "I feel different" report cannot separate a product effect from a year passing.

Waiting wins when you cannot name the measure. If you cannot say which lab value, scan, or physical test would change your mind, there is nothing to verify and nothing to compare — the honest move is to define the endpoint first.

So the winner, on the numbers available, is the monitored plan: it is the only column where the total is itemized before commitment and the readout belongs to you. When a supplement seller publishes the same 12-month figure and the same terms, the two columns become comparable and the comparison resets.

What to do next

Also worth reading: The 92% Capture Gap: Why Vendor SLA Credit Reports Fall Short: 92% Capture Gap: Why Vendor · Why Merged FM Contracts Cost 1.4x, Not 2x: The 15-30% Overlap: Why Merged FM Contracts Cost · Utility Reconciliation Drift: Why 2–4% Overcharges Persist: Utility Reconciliation Drift: Why 2–4%